Skip to content
Studies have shown that active fund managers routinely underperform the S&P500 index*
Home
Articles
WALL STREET X
Forecasts
Portfolios
Wall Street X
Articles
Forecasts
Portfolios
Search
Results for
{phrase}
(
{results_count}
of
{results_count_total}
)
Displaying
{results_count}
results of
{results_count_total}
Pharming Group N.V. (NASDAQ: PHAR)
PHAR Stock Predictions and Ratings
WSX Rating:
BUY
WSX Forecast (1yr):
11.30%
Analyst Rating:
STRONG BUY
Analyst Forecast (1yr):
204%
PHAR Stock Analysis
PHAR
PE Ratio:
65.2
PHAR
PEG Ratio:
2.3
PHAR
Forward EPS Growth (12 month):
28.20%
PHAR
PS Ratio:
2
PHAR
PSG Ratio:
0.4
PHAR
Forward Revenue Growth (12 month):
4.80%
PHAR Articles
No data was found